2 Undervalued Biotechs Vying for a Big Market
Gilead and Intercept are both developing drugs aimed at a $10 billion market opportunity in liver-disease treatment, but they present different considerations for biotech investors.
Gilead and Intercept are both developing drugs aimed at a $10 billion market opportunity in liver-disease treatment, but they present different considerations for biotech investors.
Stefan Quenneville: We recently put out a report on the therapeutic area of NASH. NASH stands for nonalcoholic steatohepatitis, which is really just a fancy way of saying fatty liver disease.
So, what is NASH? NASH is a very common but severe liver disease closely related to obesity and diabetes that has really no viable treatments currently.
What happens in NASH is that fatty deposits in the liver cause liver damage and scaring called fibrosis. So, what drug developers are doing is they are looking for drugs that can either stop or reverse the process of fibrosis. Given the millions of people that suffer from this, we think that a drug that can do that can serve a market opportunity of about $10 billion. Clearly, with an opportunity that big, there are a lot of biotech and pharma companies looking to develop drugs in NASH.
There are two things I'd like to highlight for investors who want to play the NASH opportunity; for investors with a higher risk tolerance, we like Intercept Pharma (ICPT), whose primary drug is in Phase III trials and is the most advanced drug in development for NASH currently. This is more of a binary outcome, so investors are taking on a lot of clinical risk where the results of that Phase III trial will come out in 2018, and it will be either a very strong showing or a weaker showing. So, there is both upside and downside risk in that name. But we do like the current risk/reward profile. We have it as a no-moat company, and it's currently trading at about a 50% discount to our fair value estimate.
Another less-binary way to play the NASH opportunity is through Gilead (GILD). Gilead has several earlier-stage drugs in development for NASH as well as several blockbuster drugs and other indications as part of their portfolio. So, there is less upside in the NASH opportunity but also less binary risk. We currently rate Gilead as a wide-moat company, and it's trading at about 30% discount to our fair value estimate.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.